Donna Neuberg

Senior Lecturer
This email address is being protected from spambots. You need JavaScript enabled to view it.



Donna Neuberg is involved in collaborative research in cancer in two different settings. She is the coordinating statistician for the Eastern Cooperative Oncology Group (ECOG), where she works with multi-center clinical trials in breast cancer. She also works with researchers in autologous and allogeneic bone marrow transplantation for hematologic malignancies at the Dana-Farber Cancer Institute, where issues of detection of minimal residual disease after curative therapy and the late complications of therapy are of particular interest.


Dr. Neuberg's methodological interests reflect her collaborative interests. She is currently involved in an examination of intermediate endpoints in controlled clinical trials, and, in particular, the reliability of time to progression or relapse as an indicator of improved survival. She is also exploring the recruitment of elderly patients to cancer clinical trials, using the ECOG database. Dr. Neuberg is also interested the efficient design of early phase clinical trials with multiple endpoints, and in the problems surrounding the analysis of data with missing observations over time.



Dr. Neuberg received her ScD in biostatistics from Harvard School of Public Health in 1988. She joined the Department of Biostatistical Science at DFCI in 1987. She has served as statistician for several solid tumor disease sites and for leukemia in the Eastern Cooperative Oncology Group. She works with the Lymphoma, Leukemia, and Pediatric Oncology Programs at DFCI.


Select Publications

Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest 2013; Aug 5 [Epub ahead of print].


Gagne V, Rousseau J, Labuda M, Sharif-Askari B, Brukner I, Laverdiere C, Ceppi F, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res. 2013; Aug 1 [Epub ahead of print].


Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma. Haematologica. 2013 May 3. [Epub ahead of print]


Leblebjian H, Deangelo DJ, Skirvin JA, Stone RM, Wadleigh M, Werner L, Neuberg DS, Bartel S, McDonnell AM. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2013 May 1.


Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT. Trends in all-cause mortality among patients with chronic myeloid leukemia: A Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013 Apr 26.


Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM. Prospective Study of the Efficacy of Breast Magnetic Resonance Imaging and Mammographic Screening in Survivors of Hodgkin Lymphoma. J  Clin Oncol. 2013 Apr 22. [Epub ahead of print] 

Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT. TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2013 May;3(5):564-577. Epub 2013 Mar 7.


Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14;152(4):714-26.


Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20;31(9):1202-10


Nathan DG, Field J, Lin G, Neuberg D, Majerus E, Onyekwere O, Keefer J, Okam M, Ross A, Linden J. Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Trans Am Clin Climatol Assoc. 2012;123:312-7; discussion 317-8.


Related Links